ArticleHereditas2025
RNF25 serves as a novel diagnostic and prognostic biomarker in multiple myeloma: a multi-cohort integrative analysis.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUbiquitination-related genes (UbRGs) play critical roles in tumor biology. However, their functions in multiple myeloma (MM) remain insufficiently explored.
methodsTranscriptomic data from public databases were integrated to identify UbRGs in MM through WGCNA, differential expression, and protein-protein interaction (PPI) analyses. Functional roles were examined by GO, KEGG, and GSEA, while immune infiltration and drug sensitivity were evaluated using CIBERSORT, ESTIMATE, and OncoPredict. UbRG expression was validated in clinical samples and cell lines by qRT-PCR and western blot, and functional effects of UbRG knockdown in MM cells were examined using CCK-8, Transwell, EdU, and TUNEL assays.
resultsRing Finger Protein 25 (RNF25) is a ubiquitination-related gene closely associated with MM, exhibiting consistent overexpression across multiple independent datasets. Elevated RNF25 expression is significantly correlated with poorer overall survival and serves as an independent adverse prognostic factor. Functional enrichment analysis revealed that RNF25 may regulate key pathways such as ATP-dependent chromatin remodeling, cell cycle progression, and ubiquitin-mediated proteolysis. Immune analysis further indicated that high RNF25 expression is associated with reduced immune and stromal scores, increased plasma cell infiltration, and elevated T cell co-inhibition activity. RNF25 was highly expressed in tumor tissues from clinical samples, and its knockdown significantly reduced the viability, proliferation, and migration of U266 cells, while promoting apoptosis.
conclusionsRNF25 may serve as a potential prognostic biomarker for MM and holds promise as a candidate therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.